Small molecule inhibitors of α-synuclein filament assembly

被引:312
作者
Masuda, Masami
Suzuki, Nobuyuki
Taniguchi, Sayuri
Oikawa, Takayuki
Nonaka, Takashi
Iwatsubo, Takeshi
Hisanaga, Shin-ichi
Goedert, Michel
Hasegawa, Masato
机构
[1] Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan
[2] Tokyo Metropolitan Univ, Mol Neurosci Lab, Grad Sch Sci, Hachioji, Tokyo 1920397, Japan
[3] Daiichi Pharmaceut Co Ltd, New Prod Res Lab 2, Edogawa Ku, Tokyo 1348630, Japan
[4] Univ Tokyo, Dept Neuropathol & Neurosci, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[5] MRC, Mol Biol Lab, Cambridge CB2 2QH, England
基金
英国医学研究理事会;
关键词
D O I
10.1021/bi0600749
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha-Synuclein is the major component of the filamentous inclusions that constitute defining characteristics of Parkinson's disease and other alpha-synucleinopathies. Here we have tested 79 compounds belonging to 12 different chemical classes for their ability to inhibit the assembly of alpha-synuclein into filaments in vitro. Several polyphenols, phenothiazines, porphyrins, polyene macrolides, and Congo red and its derivatives, BSB and FSB, inhibited alpha-synuclein filament assembly with IC50 values in the low micromolar range. Many compounds that inhibited alpha-synuclein assembly were also found to inhibit the formation of A ss and tau filaments. Biochemical analysis revealed the formation of soluble oligomeric alpha-synuclein in the presence of inhibitory compounds, suggesting that this may be the mechanism by which filament formation is inhibited. Unlike alpha-synuclein filaments and protofibrils, these soluble oligomeric species did not reduce the viability of SH-SY5Y cells. These findings suggest that the soluble oligomers formed in the presence of inhibitory compounds may not be toxic to nerve cells and that these compounds may therefore have therapeutic potential for alpha-synucleinopathies and other brain amyloidoses.
引用
收藏
页码:6085 / 6094
页数:10
相关论文
共 77 条
[71]   MOLECULAR-CLONING OF CDNA-ENCODING AN UNRECOGNIZED COMPONENT OF AMYLOID IN ALZHEIMER-DISEASE [J].
UEDA, K ;
FUKUSHIMA, H ;
MASLIAH, E ;
XIA, Y ;
IWAI, A ;
YOSHIMOTO, M ;
OTERO, DAC ;
KONDO, J ;
IHARA, Y ;
SAITOH, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11282-11286
[72]   Structure and dynamics of micelle-bound human α-synuclein [J].
Ulmer, TS ;
Bax, A ;
Cole, NB ;
Nussbaum, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (10) :9595-9603
[73]   Zeroing in on the pathogenic form of α-synuclein and its mechanism of neurotoxicity in Parkinson's disease [J].
Volles, MJ ;
Lansbury, PT .
BIOCHEMISTRY, 2003, 42 (26) :7871-7878
[74]   α-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy [J].
Wakabayashi, K ;
Yoshimoto, M ;
Tsuji, S ;
Takahashi, H .
NEUROSCIENCE LETTERS, 1998, 249 (2-3) :180-182
[75]   NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded [J].
Weinreb, PH ;
Zhen, WG ;
Poon, AW ;
Conway, KA ;
Lansbury, PT .
BIOCHEMISTRY, 1996, 35 (43) :13709-13715
[76]   The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia [J].
Zarranz, JJ ;
Alegre, J ;
Gómez-Esteban, JC ;
Lezcano, E ;
Ros, R ;
Ampuero, I ;
Vidal, L ;
Hoenicka, J ;
Rodriguez, O ;
Atarés, B ;
Llorens, V ;
Tortosa, EG ;
del Ser, T ;
Muñoz, DG ;
de Yebenes, JG .
ANNALS OF NEUROLOGY, 2004, 55 (02) :164-173
[77]   The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils [J].
Zhu, M ;
Rajamani, S ;
Kaylor, J ;
Han, S ;
Zhou, FM ;
Fink, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (26) :26846-26857